A Translational Large Animal Model for Antibody-Based Therapeutics
Göttingen Minipigs are particularly known for their small size, genetics and health status, and are selected for all aspects of pharmaceutical research due to their similarity to humans and access to background data.
The Humanised IgG1/IgG4 Göttingen Minipigs carry a mini-repertoire of human genes and show tolerance to a broad range of human antibodies. This opens up the possibilities of testing therapeutic antibodies in large animal models as an important alternative to non-human primates. Göttingen Minipigs are widely accepted as a pre-clinical non-rodent model and have proven their suitability in terms of handling and dosing, as well as data validity. Also, it is easy to incorporate the 3Rs when working with Göttingen Minipigs, as they are adaptable, easy to train, and you can get many data points from a single animal.
The Humanized IgG1/IgG4 Göttingen Minipigs possess the same qualities as the standard Göttingen Minipigs, but have additional benefits due to the genetic modification:
Benefits of all Göttingen Minipigs:
- Small size
- Genetics
- Background data
- Similarity to humans
- Barrier bred in AAALAC accredited facility and with high health status
- Availability in large uniform groups
Additional benefits of Humanized IgG Göttingen Minipigs:
- Safety assessments of human IgG-based therapeutic antibodies (tAbs)
- Reflects the difference in immunogenicity of different approved tAbs
- Confirmed trait inheritance
- Immunocompetent
Download whitepaper on the Humanized IgG1/IgG4 Göttingen Minipigs.
